Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Precision BioSciencesDTIL +1.01%48 Equity-to-Asset is 0.36 as of Jun. 2026, which is 3% below its 10-year median of 0.37. GuruFocus rates DTIL with a GF Score™ of 48/100 and a GF Value™ of $1.89 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,413 Biotechnology companies, Precision BioSciences ranks worse than 76.08% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Precision BioSciences Equity-to-Asset Related Terms
Precision BioSciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Precision BioSciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DTIL vs NERV, VYGR, GLSI: Equity-to-Asset Comparison
For the Biotechnology subindustry, Precision BioSciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Precision BioSciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences (DTIL) has a Equity-to-Asset of 0.36 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Precision BioSciences and its competitors. This is near median its historical median of 0.37. According to the industry distribution chart, Precision BioSciences ranks #1075 out of 1413 companies in the Biotechnology industry, placing it in the top 76.1%.
Is Precision BioSciences' Equity-to-Asset too high?
Precision BioSciences' current Equity-to-Asset of 0.36 is near median its 10-year median of 0.37. The Biotechnology industry median Equity-to-Asset is 0.68. Precision BioSciences' value of 0.36 is 47.1% below this industry median. Based on the distribution chart, Precision BioSciences ranks #1075 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Precision BioSciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Equity-to-Asset compare to NERV and VYGR?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #1075 out of 1413 companies for Equity-to-Asset. This places Precision BioSciences in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Precision BioSciences' value of 0.36 is 47.1% below this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 0.68, Precision BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precision BioSciences's current Equity-to-Asset of 0.36 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Precision BioSciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precision BioSciences's current Equity-to-Asset is 0.36, which is near median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.89, compared to a current price of $7.52 — trading 297.9% above its estimated fair value. The current Equity-to-Asset is 0.36, which is near median its 10-year median of 0.37 and 47.1% below the Biotechnology industry median of 0.68. Precision BioSciences' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current Equity-to-Asset is 0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (DTIL) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of $7.52 is trading 297.9% above its estimated GF Value™ of $1.89.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for DTIL:
Equity-to-Asset: 0.36 (near median its 10-year median of 0.37)
GF Value™: $1.89 vs. price of $7.52 (297.9% above fair value)
Industry Position: 47.1% below the Biotechnology median (#1075 of 1413)
No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
48GF Score
Get the complete analysis for DTIL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTIL has been successfully added to your 
